UK. "How do we retain OST patients in treatment?"
UK. "How do we retain OST patients in treatment?"
In a recent Clinical Update editor Tom Jones summarises and comments on a primary care cohort study in the United Kingdom - a study that considers whether the use of methadone or buprenorphine as opioid substitution treatment (OST) was associated with a greater reduction in the risk of all-cause mortality and opioid drug-related poisoning mortality. In commenting on the paper, he considers the wider question - how do we retain patients on OST in treatment? (SMMGP - Großbritannien. Substance Misuse Management in General Practice, UK, 18.10.2018)
The impact of buprenorphine and methadone on mortality: a primary care cohort study in the United Kingdom.
Hickman M., Steer C., Tilling K., Lim A. G., Marsden J., Millar T., Strang J., Telfer M., Vickerman P. & Macleod J. (2018) Addiction, 113(8): 1461-1476. doi: 10.1111/add.14188.
https://smmgp.org.uk/news/2018/clinical-update-extract-oct-18/